Correlation Between Pulmatrix and Moleculin Biotech

Can any of the company-specific risk be diversified away by investing in both Pulmatrix and Moleculin Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pulmatrix and Moleculin Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Pulmatrix and Moleculin Biotech, you can compare the effects of market volatilities on Pulmatrix and Moleculin Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pulmatrix with a short position of Moleculin Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pulmatrix and Moleculin Biotech.

Diversification Opportunities for Pulmatrix and Moleculin Biotech

0.42

Correlation Coefficient

Pulmatrix  Moleculin Biotech

Very weak diversification

The 3 months correlation between Pulmatrix and Moleculin is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Pulmatrix and Moleculin Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Moleculin Biotech and Pulmatrix is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pulmatrix are associated (or correlated) with Moleculin Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Moleculin Biotech has no effect on the direction of Pulmatrix i.e., Pulmatrix and Moleculin Biotech go up and down completely randomly.

Pair Corralation between Pulmatrix and Moleculin Biotech

Given the investment horizon of 90 days Pulmatrix is expected to generate 2.07 times more return on investment than Moleculin Biotech. However, Pulmatrix is 2.07 times more volatile than Moleculin Biotech. It trades about 0.21 of its potential returns per unit of risk. Moleculin Biotech is currently generating about 0.01 per unit of risk. If you would invest  179.00  in Pulmatrix on September 12, 2024 and sell it today you would earn a total of  417.00  from holding Pulmatrix or generate 232.96% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Pulmatrix  vs.  Moleculin Biotech

Pulmatrix

Risk-Adjusted Performance

16 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Pulmatrix are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Pulmatrix displayed solid returns over the last few months and may actually be approaching a breakup point.

Moleculin Biotech

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Moleculin Biotech are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Moleculin Biotech is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Pair Trading with Pulmatrix and Moleculin Biotech

The main advantage of trading using opposite Pulmatrix and Moleculin Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pulmatrix position performs unexpectedly, Moleculin Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Moleculin Biotech will offset losses from the drop in Moleculin Biotech's long position.

The idea behind Pulmatrix and Moleculin Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.